Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

As a result of the stop work order, Vaxart said it had been forced to lay off 10% of its workforce. The company entered the ...

As the U.S. cuts federal research funding and infrastructure, European countries are strategizing ways to attract top ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...

At its annual artificial intelligence-focused GTC conference in San Jose, Nvidia outlined several collaborations with medtech ...

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

After serving as the director of the National Human Genome Research Institute (NHGRI) for more than 15 years, Eric Green, M.D ...

About three months after leaving her post as the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., has found a new ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...